5 results match your criteria: "Northwestern University Feinberg School of Medicine. Evanston[Affiliation]"
Objective: Although severe hypoglycaemia (SH) can lead to adverse health outcomes, little is known about its occurrence and re-occurrence among youth with type 1 or type 2 diabetes.
Methods: This study included 2740 participants aged <20 years at diabetes diagnosis and 5-14 years diabetes duration from the SEARCH for Diabetes in Youth Cohort Study. Participants reported SH events in the past 6 months.
The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers.
J Law Med Ethics
June 2018
Jalayne J. Arias, J.D., M.A., is an Assistant Professor in the Department of Neurology at the University of California - San Francisco and an Atlantic Fellow at the Global Brain Health Institute. Ms. Arias received her B.A. from Pepperdine University (Malibu, CA), her J.D. from Arizona State University (Tempe, AZ), and an M.A. in Bioethics at Case Western University (Cleveland, OH). Ana M. Tyler, J.D., M.A., is a Clinical Ethicist at Beaumont Health (Detroit, MI). She was previously the Clinical Ethics Fellow at California Pacific Medical Center (San Francisco, CA). She received her B.A. from The Ohio State University (Columbus, OH), and received her J.D., with a concentration in Health Law and Policy and her Master's degree in Bioethics from Case Western Reserve University (Cleveland, OH). Benjamin J. Oster, J.D., LL.M., M.S., is an Associate with the Cleveland Clinic Foundation Innovations group. Mr. Oster received his B.S. from The Ohio State University (Columbus, OH), his M.S. from Georgetown University Graduate School of Arts & Sciences (Washington, D.C.), his J.D. from Case Western Reserve University School of Law (Cleveland, OH), and his LL.M. from Duke University School of Law (Durham, NC). Jason Karlawish, M.D., is a Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania Perelman School of Medicine. Dr. Karlawish received his B.S. from Northwestern University (Evanston, IL) and his M.D. from Northwestern University Feinberg School of Medicine (Evanston, IL). He completed residency at Johns Hopkins Bayview Medical Center (Baltimore, MD) and fellowship at University of Chicago Medical Center (Chicago, IL).
Previously diagnosed by symptoms alone, Alzheimer's disease is now also defined by measures of amyloid and tau, referred to as "biomarkers." Biomarkers are detectible up to twenty years before symptoms present and open the door to predicting the risk of Alzheimer's disease. While these biomarkers provide information that can help individuals and families plan for long-term care services and supports, insurers could also use this information to discriminate against those who are more likely to need such services.
View Article and Find Full Text PDFSuccess of a comprehensive school-based asthma intervention on clinical markers and resource utilization for inner-city children with asthma in Chicago: the Mobile C.A.R.E. Foundation's asthma management program.
J Asthma
March 2007
Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine. Evanston, Illinois, USA.
Children with asthma in low-income households in Chicago were participants in a school-based mobile van clinic, Mobile C.A.R.
View Article and Find Full Text PDFElevating our therapeutic expectations in overactive bladder.
J Am Acad Nurse Pract
October 2004
Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine Evanston, Illinois, USA.
Drug therapy for overactive bladder (OAB) most commonly includes antimuscarinic agents, which work by relaxing bladder smooth muscle through inhibition of acetylcholine receptors in the bladder. The major adverse effects with existing antimuscarinic agents are anticholinergic in nature (e.g.
View Article and Find Full Text PDF